Functional Characterization of the A411T (L137F) and G364A (D122N) Genetic Polymorphisms in Human N-acetyltransferase 2

Overview

Journal Pharmacogenet Genomics

Specialties Genetics
Pharmacology

Date 2007 Feb 1

PMID 17264801

Citations 11

Authors

Yu Zang

Shuang Zhao

Mark A Doll

J Christopher States

David W Hein

Affiliations

Soon will be listed here.

Abstract

Objectives: Human N-acetyltransferase 2 (NAT2) genetic polymorphisms may modify drug efficacy and toxicity and cancer susceptibility from carcinogen exposure. Two human NAT2 alleles, NAT2*5I and NAT2*12D, were identified recently. In NAT2*5I, a new single nucleotide polymorphism AT (L137F) was found coexisting with single nucleotide polymorphisms TC (I114T), CT (silent) and AG (K268R). The other allele NAT2*12D consists of a new single nucleotide polymorphism GA (D122N) together with AG (K268R). We undertook a study to characterize these new single nucleotide polymorphisms and NAT2 alleles to further our understanding of genotype/phenotype relationships in human populations.

Methods: Various human NAT2 alleles were cloned and recombinantly expressed in COS-1 cells and the effects of single nucleotide polymorphisms on NAT2 expression were determined. To further test our hypothesis that AT (L137F) and GA (D122N) accelerate protein degradation, various NAT2 alleles were cloned and expressed in Escherichia coli, which does not possess the ubiquitin-mediated degradation pathway.

Results: Both AT and GA reduced NAT2 immuno-reactive protein to an undetectable level without causing changes in mRNA level. Missense mutants displayed different effects on sulfamethazine N-acetylation activity for both L137 (wild-type: 70.2+/-5.2 nmol/min/mg; L137F: 1.34+/-0.03 nmol/min/mg; L137W: nondetectable; L137I: 34.2+/-2.0 nmol/min/mg; L137G: 0.52+/-0.04 nmol/min/mg) and D122 (wild-type: 70.2+/-5.2 nmol/min/mg; D122R: non-detectable; D122Q: non-detectable; D122E: 1.72+/-0.24 nmol/min/mg). In contrast to the expression in mammalian cells, recombinant NAT2 possessing either of these two single nucleotide polymorphisms showed no reduction in immuno-reactive NAT2 level when expressed in E. coli.

Conclusions: These findings suggest that both AT (L137F) and GA (D122N) enhance NAT2 degradation, resulting in reduced NAT2 protein and catalytic activity for NAT2 5I and NAT2 12D.

Citing Articles

The actinobacterium Tsukamurella paurometabola has a functionally divergent arylamine N-acetyltransferase (NAT) homolog.

Garefalaki V, Kontomina E, Ioannidis C, Savvidou O, Vagena-Pantoula C, Papavergi M World J Microbiol Biotechnol. 2019; 35(11):174.

PMID: 31673919 DOI: 10.1007/s11274-019-2755-1.

Comparative analysis of xenobiotic metabolising N-acetyltransferases from ten non-human primates as in vitro models of human homologues.

Tsirka T, Konstantopoulou M, Sabbagh A, Crouau-Roy B, Ryan A, Sim E Sci Rep. 2018; 8(1):9759.

PMID: 29950659 PMC: 6021393. DOI: 10.1038/s41598-018-28094-6.

Xenobiotic-metabolizing enzymes in Bacillus anthracis: molecular and functional analysis of a truncated arylamine N-acetyltransferase isozyme.

Kubiak X, Duval R, Pluvinage B, Chaffotte A, Dupret J, Rodrigues-Lima F Br J Pharmacol. 2016; 174(14):2174-2182.

PMID: 27846346 PMC: 5481644. DOI: 10.1111/bph.13647.

NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.

Yuliwulandari R, Susilowati R, Wicaksono B, Viyati K, Prayuni K, Razari I J Hum Genet. 2016; 61(6):533-7.

PMID: 26911349 DOI: 10.1038/jhg.2016.10.

Structural and biochemical characterization of an active arylamine N-acetyltransferase possessing a non-canonical Cys-His-Glu catalytic triad.

Kubiak X, Li de la Sierra-Gallay I, Chaffotte A, Pluvinage B, Weber P, Haouz A J Biol Chem. 2013; 288(31):22493-505.

PMID: 23770703 PMC: 3829337. DOI: 10.1074/jbc.M113.468595.

References

Leff M, Fretland A, Doll M, Hein D . Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. J Biol Chem. 1999; 274(49):34519-22. DOI: 10.1074/jbc.274.49.34519. View

Wang H, Liu L, Hanna P, Wagner C . Catalytic mechanism of hamster arylamine N-acetyltransferase 2. Biochemistry. 2005; 44(33):11295-306. DOI: 10.1021/bi047564q. View

Hein D, Doll M, Fretland A, Leff M, Webb S, Xiao G . Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000; 9(1):29-42. View

Butcher N, Ilett K, Minchin R . Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol Pharmacol. 2000; 57(3):468-73. DOI: 10.1124/mol.57.3.468. View

Sinclair J, Sandy J, Delgoda R, Sim E, Noble M . Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nat Struct Biol. 2000; 7(7):560-4. DOI: 10.1038/76783. View

de Leon J, Vatsis K, Weber W . Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1. Mol Pharmacol. 2000; 58(2):288-99. DOI: 10.1124/mol.58.2.288. View

Siegel D, Anwar A, Winski S, Kepa J, Zolman K, Ross D . Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol. 2001; 59(2):263-8. DOI: 10.1124/mol.59.2.263. View

Fretland A, Leff M, Doll M, Hein D . Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics. 2001; 11(3):207-15. DOI: 10.1097/00008571-200104000-00004. View

Delomenie C, Goodfellow G, Grant D, Dupret J . Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: evidence for the conservation of a cysteine protease catalytic domain and an active-site loop. Biochem J. 2001; 356(Pt 2):327-34. PMC: 1221842. DOI: 10.1042/0264-6021:3560327. View

10.

Le Marchand L, Hankin J, Wilkens L, Pierce L, Franke A, Kolonel L . Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2001; 10(12):1259-66. View

11.

Rodrigues-Lima F, Dupret J . 3D model of human arylamine N-acetyltransferase 2: structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop. Biochem Biophys Res Commun. 2002; 291(1):116-23. DOI: 10.1006/bbrc.2002.6414. View

12.

Sandy J, Mushtaq A, Kawamura A, Sinclair J, Sim E, Noble M . The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis--an enzyme which inactivates the anti-tubercular drug, isoniazid. J Mol Biol. 2002; 318(4):1071-83. DOI: 10.1016/S0022-2836(02)00141-9. View

13.

Hein D . Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res. 2002; 506-507:65-77. DOI: 10.1016/s0027-5107(02)00153-7. View

14.

Hein D, Leff M, Ishibe N, Sinha R, Frazier H, Doll M . Association of prostate cancer with rapid N-acetyltransferase 1 (NAT1*10) in combination with slow N-acetyltransferase 2 acetylator genotypes in a pilot case-control study. Environ Mol Mutagen. 2002; 40(3):161-7. DOI: 10.1002/em.10103. View

15.

van der Hel O, Peeters P, Hein D, Doll M, Grobbee D, Kromhout D . NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics. 2003; 13(7):399-407. DOI: 10.1097/00008571-200307000-00005. View

16.

Zhu J, Chang P, Bondy M, Sahin A, Singletary S, Takahashi S . Detection of 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine-DNA adducts in normal breast tissues and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2003; 12(9):830-7. View

17.

Butcher N, Arulpragasam A, Minchin R . Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: a mechanism for the slow acetylator phenotype and substrate-dependent down-regulation. J Biol Chem. 2004; 279(21):22131-7. DOI: 10.1074/jbc.M312858200. View

18.

Klucken J, Shin Y, Masliah E, Hyman B, McLean P . Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem. 2004; 279(24):25497-502. DOI: 10.1074/jbc.M400255200. View

19.

Weber W, Hein D . N-acetylation pharmacogenetics. Pharmacol Rev. 1985; 37(1):25-79. View

20.

Grant D, Blum M, Beer M, Meyer U . Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol. 1991; 39(2):184-91. View